These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18729777)

  • 21. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
    Keitel WA; Treanor JJ; El Sahly HM; Gilbert A; Meyer AL; Patriarca PA; Cox MM
    Vaccine; 2009 Dec; 28(2):379-85. PubMed ID: 19879222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
    Sambhara V
    J Infect Dis; 2011 Jun; 203(11):1697-8. PubMed ID: 21593002
    [No Abstract]   [Full Text] [Related]  

  • 25. Broadly neutralizing influenza antibodies elicited through prime–boost vaccination in animal study.
    Patel J
    Expert Rev Vaccines; 2012 Oct; 11(10):1167. PubMed ID: 23320261
    [No Abstract]   [Full Text] [Related]  

  • 26. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in antibody responses of mice to intranasal or intraperitoneal immunization with influenza A virus and vaccination with subunit influenza vaccine.
    Fislová T; Sládková T; Gocník M; Mucha V; Varecková E; Kostolanský F
    Acta Virol; 2005; 49(4):243-50. PubMed ID: 16402681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.
    Lee VJ; Tay JK; Chen MI; Phoon MC; Xie ML; Wu Y; Lee CX; Yap J; Sakharkar KR; Sakharkar MK; Lin RT; Cui L; Kelly PM; Leo YS; Tan YJ; Chow VT
    Vaccine; 2010 Oct; 28(42):6852-7. PubMed ID: 20723626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years.
    Nabeshima S; Kashiwagi K; Murata M; Kanamoto Y; Furusyo N; Hayashi J
    J Med Virol; 2007 Mar; 79(3):320-5. PubMed ID: 17245715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A; Rodriguez MA; Fayad LE; Rodriguez GH; Pro B; Wang M; Romaguera JE; Goy AH; Hagemeister FB; McLaughlin P; Bodey GP; Kwak LW; Raad II; Couch RB
    J Infect Dis; 2006 Nov; 194(10):1394-7. PubMed ID: 17054068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
    Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influenza vaccine immunology.
    Dormitzer PR; Galli G; Castellino F; Golding H; Khurana S; Del Giudice G; Rappuoli R
    Immunol Rev; 2011 Jan; 239(1):167-77. PubMed ID: 21198671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of seasonal vaccine hemagglutinin subtype 1 (H1) epitopes in Mexican isolates of the new influenza A (H1N1) 2009 virus.
    Rodríguez-Alvarez M; Velasco-Velasco AM; Alvarez-Anell NJ; Jiménez-Corona ME; de León-Rosales SP
    Arch Med Res; 2009 Nov; 40(8):687-92. PubMed ID: 20304258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets.
    Huber VC; McCullers JA
    J Infect Dis; 2006 Mar; 193(5):677-84. PubMed ID: 16453263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum immunoglobulin levels do not affect antibody responses to influenza HA vaccine in preterm infants.
    Sasaki Y; Kusuhara K; Saito M; Hikino S; Murayama Y; Yamashita H; Matsumoto N; Kukita J; Kinukawa N; Hara T
    Vaccine; 2006 Mar; 24(12):2208-12. PubMed ID: 16325309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.